Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Breast Cancer Remotely Imposes a Myeloid Bias on Haematopoietic Stem Cells by Reprogramming the Bone Marrow Niche

[Nature Cell Biology] Using unbiased transcriptomic analysis and in situ imaging of HSCs and the bone marrow niche during breast cancer, researchers showed that both HSCs and mesenchymal stem cells were transcriptionally and spatially modified.

RAB27B-Regulated Exosomes Mediate LSC Maintenance via Resistance to Senescence and Crosstalk with the Microenvironment

[Leukemia] Investigators found that increased RAB27B in leukemia stem cells prevented their senescence and maintained their stemness in vitro and in vivo.

ROBO1 Deficiency Impairs HSPC Homeostasis and Erythropoiesis via CDC42 and Predicts Poor Prognosis in MDS

[Science Advances] Robo1 deficiency impaired HSPC homeostasis and disrupted HSPC pool, especially the reduction of megakaryocyte erythroid progenitors, which caused a blockage in the early stages of erythropoiesis in mice.

Data-Driven Grading of Acute Graft-Versus-Host Disease

[Nature Communications] The authors analyzed acute graft-versus-host disease phenotypes and clinical classifications in depth in large, multicenter cohorts involving 3019 patients, and addressed prevailing gaps by developing data-driven models.

SRSF2 Mutation Reduces Polycythemia and Impairs Hematopoietic Progenitor Functions in JAK2V617F-Driven Myeloproliferative Neoplasm

[Blood Cancer Journal] Scientists showed that co-expression of Srsf2P95H mutant reduced red blood cell, neutrophil, and platelet counts,and attenuated splenomegaly, but did not induce bone marrow fibrosis in the Jak2V617F/+ mice.

Montefiore Einstein Comprehensive Cancer Center Awarded FDA Grant for Clinical Trial on Experimental AML/MDS Treatment

[Albert Einstein College of Medicine] Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center were awarded a four-year, $2.6 million grant from the US FDA to conduct an innovative Phase I clinical trial of a new drug for patients with relapsed and treatment-resistant forms of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Outcomes of CMML Patients Undergoing Allo-HCT Are Significantly Worse Compared to MDS—A Study of the CMWP of the EBMT

[American Journal Of Hematology] Patients ≥18 years with chronic myelomonocytic leukemia and myelodysplastic syndromes undergoing hematopoietic cell transplantation reported to the EBMT registry were analyzed.

Most Clinical Trials Run in Canada Failed to Take Basic Steps Toward Transparency, Analysis Finds

[STAT News] Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year period were registered prospectively, reported results, and published the findings, underscoring ongoing concerns about clinical trial transparency, according to a new analysis.

Tamoxifen for the Treatment of Myeloproliferative Neoplasms: A Phase II Clinical Trial and Exploratory Analysis

[Nature Communications] TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen’s safety and activity in patients with stable myeloproliferative neoplasms, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20%.

A Prospective, Multicenter Study on Hematopoietic Stem-Cell Mobilization with Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor and ‘On-Demand’ Plerixafor in Multiple Myeloma Patients Treated with Novel...

[Haematologica] 301 patients with a median age 60 years were enrolled. Of them, 287 and 274 patients collected ≥2 and ≥4×106 CD34+ cells/kg, respectively, with a median of 9.9×106 CD34+ cells/kg collected.

Bidirectional Interplay between Metabolism and Epigenetics in Hematopoietic Stem Cells and Leukemia

[EMBO Journal] The authors provide an in-depth review of the metabolic and epigenetic interplay regulating hematopoietic stem cell fate, and discuss the influence of metabolic stress stimuli, as well as alterations occurring during leukemic development.

MorphoSys, after Saying AbbVie ‘Failed,’ Defends Own Mixed Blood Cancer Data, Plots Approval Filings

[FierceBiotech] The data come from a Phase III clinical trial of pelabresib, a BET inhibitor that MorphoSys acquired in its $1.7 billion acquisition of Constellation Pharmaceuticals.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.